Black Friday Get Elite for just $149.00 Claim Now

Dare Bioscience Misses Badly As DARE To PLAY Slips Again; Early Demand Signals Collide With A Shrinking Cash Cushion

By Earnings Whispers | November 16, 2026, 6:41 PM
Daré Bioscience, Inc. (DARE) quarterly results card
Earnings Whispers

Daré Bioscience reported a third-quarter loss of $0.18 per share, missing the -$0.13 consensus by 38.5%. Revenue of $0.05 million missed the $5.9 million consensus by 99.2%. On a year-over-year basis the numbers look better: earnings improved 35.7% from a $0.28 loss, and revenue grew 2300.0% from a negligible base. Neither comparison changes the central fact of the quarter. DARE to PLAY Sildenafil Cream, the product meant to turn Daré into a commercial company, has still not generated a dollar of revenue. Its dispensing timeline slipped once more, to late November. Daré now has early demand evidence, but not the commercial results investors were promised, and its balance sheet leaves little room for further delay.

The quality of the per-share improvement deserves scrutiny. Net loss narrowed only modestly, to $3.2 million from $3.6 million. A large part of the EPS gain came from a weighted share count that rose to 17.4 million from 12.8 million. Reported R&D expense fell to just $0.3 million, but that figure is heavily shaped by grant accounting. The company recorded $4.7 million of contra-R&D, meaning grant funding offset program costs. That flatters the expense line and also shows how dependent the pipeline remains on outside funders.

The commercial line itself is still upside down. Cost of revenues was $0.2 million, mostly DARE to PLAY medical education and awareness spending. That exceeded the roughly $48,000 in total revenue, which consisted mainly of Gates Foundation R&D services income. Flora Sync LF5 sales were described as not material. Revenue also fell sequentially from about $0.2 million in the second quarter.

The call did deliver tangible demand indicators that were absent three months ago:

  • **DARE to PLAY:** 182 office-based providers have written prescriptions, prescriptions span 48 states plus Washington, D.C., and a first in-office stocking order has arrived.
  • **Flora Sync LF5:** orders have come from 27 states, along with a first provider reorder and a 4.9-star rating on roughly 25 reviews.
  • **Flora Sync LF5 next steps:** the product was selected for Amazon's new seller program, with Amazon availability in early 2027. Two line extensions, Flora Renew and Flora Reset, are also slated for early 2027.

These are real signs of provider engagement. They are also pre-revenue signals, and management's tone was noticeably more measured than the expansive catalyst-heavy messaging of earlier calls.

The execution record is where bears have legitimate ammunition. DARE to PLAY revenue was once guided for the second quarter of 2026. It then moved to summer and the third quarter, and dispensing is now expected late this month. The initial footprint is only 28 states, compared with earlier national framing; the rest depend on the 503B partner obtaining state licenses. Revenue will also be recorded net of 503B and pharmacy costs, which limits reported scale. Management said 2026 product revenue will not be material.

The pipeline offers longer-dated optionality:

  • Ovaprene Phase 3 and DARE-HPV Phase 2 topline readouts are both targeted for 2027.
  • A new DARE-HPV patent extends protection to at least 2039.
  • Exploratory collaboration discussions are under way for the DARE-IDDS platform, including GLP-1 applications.

The Ovaprene study carries a known risk: it is proceeding with fewer than 250 completers despite the FDA's recommendation of 250.

The balance sheet is the binding constraint. Cash fell to $11.5 million from $24.7 million at year-end, and stockholders' equity is just $2.3 million. Management acknowledged earlier this year that runway was under 12 months. The third-quarter decline was a modest $1.1 million, and working capital improved to $3.2 million from a deficit in the second quarter. Even so, a write-down of deferred offering costs hints at a financing that was not completed. The release's own risk factors flag going-concern and potential Nasdaq delisting concerns. Recent grant inflows help at the margin but do not fund a multi-product launch:

  • $1.5 million for DARE-LARC1, bringing cumulative funding under that grant to about $43.3 million.
  • Roughly $0.9 million from the Gates Foundation.

The market has priced much of this skepticism in already. Shares entered the report at $0.66, down 57.6% from the $1.55 open after the August report. They sit about 57% below the 200-day moving average and just 7.8% above a 52-week low of $0.61 set on November 5. The stock has spent the entire inter-earnings period sliding from its $1.61 post-report high, and price and AVWAP trend readings remain negative. Investor sentiment is still negative but improved modestly, to -0.39 from -0.48. That suggests expectations had become depressed rather than that confidence has returned.

The bottom line is that Daré delivered a quarter of promises rather than performance. Provider uptake, multi-state prescriptions and early Flora Sync reorders give the commercial story more substance than it had in August. But a fourth consecutive slip in DARE to PLAY timing, a narrower launch footprint, negligible revenue and a dwindling cash balance mean the next quarter must show actual dispensing volume. With financing pressure looming, demand indicators alone are unlikely to be enough.

Read our earnings preview for Daré Bioscience, Inc.: https://www.earningswhispers.com/article/DARE/23150

This earnings review was originally published on Earnings Whispers.

This article is for informational purposes only and is not investment advice. Earnings Whispers and its staff may hold positions in the securities mentioned. It is AI-assisted, based on proprietary Earnings Whispers data and company reports, and edited by Earnings Whispers staff.

Mentioned In This Article

Latest News

Nov-16
Nov-16
Nov-16
Nov-11
Nov-10
Nov-09
Nov-04
Oct-30
Oct-28
Oct-26
Oct-19
Oct-13
Oct-08
Sep-28
Sep-28